Edesa Biotech shareholders approve equity plan amendment adding 750K shares

Proposal No. 3 - Approval of Amendment to the 2019 Equity Incentive Compensation Plan The shareholders approved an amendment to the Company’s 2019 Plan to (i) increase the number of shares available for issuance thereunder plan by 750,000 shares and (ii) eliminate the annual per participant option grant limit. For Against Abstain Broker Non-Votes 2,613,551 130,589 10,680 2,147,101

Proposal No. 4 - Appointment of MNP LLP as the Company’s Auditors and Independent Registered Public Accounting Firm for the Ensuing Year The shareholders approved the appointment of MNP LLP as the Company’s auditors and independent registered public accounting firm for the fiscal year ending September 30, 2026. For Withhold Broker Non-Votes 4,814,478 87,443 N/A

Proposal No. 2 - Advisory Vote on Executive Compensation The shareholders approved, on an advisory basis, the executive compensation of the named executive officers as disclosed in the proxy statement for the Annual Meeting, by the following vote. For Against Abstain Broker Non-Votes 2,670,075 69,281 15,464 2,147,101

Proposal No. 1 - Election of the Company’s Directors Based upon the following votes, the shareholders elected Joan Chypyha, David Liu, Sean MacDonald, Patrick Marshall, Pardeep Nijhawan, Charles Olson and Carlo Sistilli to serve as members of the Company’s board of directors until the annual meeting of shareholders to be held in 2027 or until their successors are duly elected and qualified. For Withhold Broker Non-Votes Joan Chypyha 2,705,856 48,964 2,147,101 David Liu 2,674,286 80,534 2,147,101 Sean MacDonald 2,674,082 80,738 2,147,101 Patrick Marshall 2,706,023 48,797 2,147,101 Pardeep Nijhawan 2,705,297 49,523 2,147,101 Charles Olson 2,705,959 48,861 2,147,101 Carlo Sistilli 2,673,724 81,096 2,147,101